Problem

Healthcare providers struggle to maintain consistent follow-up, check-ins, and monitoring after patients leave the hospital or move through other high-risk care transitions. These activities often fall through the cracks, creating care gaps and allowing manageable issues to become emergencies. For Medicare and older patients, the central pain is keeping people healthy at home without requiring care teams to manually contact and monitor every patient.

The economic case is to reduce avoidable hospitalizations and extend the reach of outpatient care teams. Kaigo’s clearest use case is post-discharge follow-up: ensuring that a recently discharged, high-risk patient is contacted, monitored, and escalated to a human team when something appears wrong.

Product / Service

Kaigo describes its product as an AI outpatient care workforce: autonomous agents that continuously follow up with, monitor, and advocate for patients, then report actionable insights to human care teams. Its delivery model combines automated phone-based check-ins with remote patient monitoring, giving providers an ongoing view of patients between office visits and after discharge.

The intended benefit is to automate repetitive outreach while preserving human oversight for issues that require intervention. In practice, Kaigo acts as an AI care coordinator for care transitions, referrals, and post-discharge follow-up, helping providers close care gaps, identify problems earlier, improve patient engagement, and keep more patients safely at home.

Market

Kaigo competes in AI-enabled outpatient care management, care coordination, post-acute follow-up, and remote patient monitoring, initially focused on Medicare and senior populations. The available materials do not name a direct competitor; the company’s practical alternatives are provider-run care-management teams, telephonic outreach programs, and other digital or AI-enabled monitoring platforms.

The company appears to be early-stage: it is identified as YC F25, and directory information describes it as a seed company founded in 2025 by Kazuki Shin, Peter Chien, and Lukas Klaiber. No public revenue, customer, deployment, or reimbursement metrics are provided in the available research, so its commercial traction is not yet quantified and it should not be labeled definitively as pre-revenue.